Background: Ipilimumab improves the survival of metastatic melanoma patients. Despite
documented, durable objective responses, a significant number of patients fails to benefit …

Background In the peripheral blood, the neutrophil–lymphocyte ratio (NLR) and platelet–
lymphocyte ratio (PLR) change in response to malignancy. These biomarkers are …

Purpose An elevated count of blood neutrophils and monocytes recently was shown
independently to predict short survival in patients with stage IV melanoma undergoing …

Background: The prognostic role of the platelet-to-lymphocyte ratio (PLR) is controversial in
patients with melanoma. Therefore, we performed a meta-analysis to assess the prognostic …

Background There is an unmet need to identify markers predictive of response to ipilimumab
in patients with melanoma because the number of responders to ipilimumab is low and its …

Several studies have reported that a high neutrophil-to-lymphocyte ratio (NLR) is associated
with poor clinical outcomes in several cancers, but this ratio has not been thoroughly studied …

Abstract Background/Objectives Elevated neutrophil‐to‐lymphocyte ratio (NLR) in
peripheral blood is associated with poor overall survival (OS) in metastatic melanoma …

Background: Immune checkpoint inhibitors (ICIs) showed promising therapeutic efficacy on
melanoma. Neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH) …

Abstract Background The Neutrophil-to-lymphocyte ratio (NLR) holds relevance in cancer
immunotherapy outcomes, yet its validation remains limited. Thus, we conducted an …

Background Since a non-negligible fraction of patients with metastatic melanoma does not
experience long-term disease control, even with immunotherapy and targeted therapy, new …